p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia
Authors
Keywords
-
Journal
LEUKEMIA
Volume 25, Issue 11, Pages 1739-1750
Publisher
Springer Nature
Online
2011-06-24
DOI
10.1038/leu.2011.159
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- p53 Lesions in Leukemic Transformation
- (2011) Ashot Harutyunyan et al. NEW ENGLAND JOURNAL OF MEDICINE
- AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3
- (2010) M Wunderlich et al. LEUKEMIA
- Decitabine Maintains Hematopoietic Precursor Self-Renewal by Preventing Repression of Stem Cell Genes by a Differentiation-Inducing Stimulus
- (2010) Z. Hu et al. MOLECULAR CANCER THERAPEUTICS
- A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
- (2010) Paul W. Hollenbach et al. PLoS One
- Differentiation therapy of leukemia: 3 decades of development
- (2009) D. Nowak et al. BLOOD
- Undifferentiated hematopoietic cells are characterized by a genome-wide undermethylation dip around the transcription start site and a hierarchical epigenetic plasticity
- (2009) Y. S. Chung et al. BLOOD
- Chemical Decomposition of 5-Aza-2′-deoxycytidine (Decitabine): Kinetic Analyses and Identification of Products by NMR, HPLC, and Mass Spectrometry
- (2009) Daniel K. Rogstad et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Mouse models of human AML accurately predict chemotherapy response
- (2009) J. Zuber et al. GENES & DEVELOPMENT
- Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
- (2009) David P. Steensma et al. JOURNAL OF CLINICAL ONCOLOGY
- Epigenetic Therapies Move Into New Territory, but How Exactly Do They Work?
- (2009) R. S. Tuma JNCI-Journal of the National Cancer Institute
- Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications
- (2009) Ruth Halaban et al. PLoS One
- Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells
- (2008) D. C. Taussig et al. BLOOD
- Stem cell concepts renew cancer research
- (2008) J. E. Dick BLOOD
- Microenvironment Determines Lineage Fate in a Human Model of MLL-AF9 Leukemia
- (2008) Junping Wei et al. CANCER CELL
- Modeling of C/EBPα Mutant Acute Myeloid Leukemia Reveals a Common Expression Signature of Committed Myeloid Leukemia-Initiating Cells
- (2008) Peggy Kirstetter et al. CANCER CELL
- Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rγnull mice generate a faster and more efficient disease compared to other NOD/scid-related strains
- (2008) Alice Agliano et al. INTERNATIONAL JOURNAL OF CANCER
- Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype
- (2008) C Haferlach et al. LEUKEMIA
- The genetics of the p53 pathway, apoptosis and cancer therapy
- (2008) Alexei Vazquez et al. NATURE REVIEWS DRUG DISCOVERY
- p21WAF1/CIP1 induction by 5-azacytosine nucleosides requires DNA damage
- (2008) A Jiemjit et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now